Kesimpta offers effective and well-tolerated treatment options for multiple sclerosis. This innovative therapy helps manage symptoms and slow disease progression, improving patients’ quality of life. With its ease of use and proven results, Kesimpta is transforming MS treatment and care.
Self-Administered and Effective
Kesimpta, a once-monthly self-administered injection, revolutionizes the treatment of relapsing-remitting multiple sclerosis (RRMS). It is a monoclonal antibody that binds to a docking site (CD20) on some immune B cells and depletes them. Its remarkable efficacy in reducing annualized relapse rates and MRI-detected disease activity is supported by compelling clinical evidence.1
Superior Efficacy and Safety
Compared to other injectable therapies for RRMS, Kesimpta stands out with its superior efficacy. It has shown significant reductions in relapse rates, lesions on MRI scans, and disability progression compared to other treatments. Moreover, its favorable safety profile ensures peace of mind during treatment.
Well-Tolerated With Low Side-Effect Risk
Kesimpta’s safety profile is well-established through rigorous clinical trials. It is generally well-tolerated, with a low incidence of adverse events. Notably, there is no increased risk of serious infections associated with Kesimpta compared to placebo.2
Learn More About Multiple Sclerosis Treatments
Don’t let Multiple Sclerosis hold you back any longer. Take charge of your health and explore the possibilities of Kesimpta. Learn more to gather more information, understand the treatment process, and consult with healthcare professionals. Empower yourself with knowledge and experience the freedom from relapses that Kesimpta offers.